Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) in Human Obesity (OBEPALIP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01138774 |
Recruitment Status :
Completed
First Posted : June 7, 2010
Last Update Posted : May 28, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity Body Fat Insulin Resistance | Dietary Supplement: Double blind dietary intervention with EPA and lipoic acid | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 103 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | December 2011 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Control group
Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
|
Dietary Supplement: Double blind dietary intervention with EPA and lipoic acid
Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA). |
Experimental: EPA group
Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
|
Dietary Supplement: Double blind dietary intervention with EPA and lipoic acid
Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA). |
Experimental: Lipoic acid group
Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
|
Dietary Supplement: Double blind dietary intervention with EPA and lipoic acid
Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA). |
Experimental: EPA+LA group
Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
|
Dietary Supplement: Double blind dietary intervention with EPA and lipoic acid
Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA). |
- Weight Loss [ Time Frame: Week 0 (baseline) ]Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.
- Weight Loss [ Time Frame: Week 2 ]Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.
- Weight Loss [ Time Frame: Week 4 ]Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.
- Weight Loss [ Time Frame: week 6 ]Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.
- Weight Loss [ Time Frame: Week 8 ]Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.
- Weight Loss [ Time Frame: Week 10 (end of treatment) ]Volunteers will attend the Nutritional Intervention unit (University of Navarra), where their weight will be measured to the nearest 0.1 kg.
- Body composition and Anthropometric parameters [ Time Frame: Week 0 (Baseline) ]Changes in body composition will be analyzed by Dual X-ray Absorptiometry (DXA) and by bioimpedance, and hip and waist circumferences will be measured.
- Body composition and anthropometric parameters [ Time Frame: Week 10 (end of treatment) ]Changes in body composition will be analyzed by Dual X-ray Absorptiometry (DXA) and by bioimpedance, and hip and waist circumferences will be measured.
- Glucose metabolism parameters [ Time Frame: Week 0 (baseline) ]Fasting serum glucose, Fasting serum insulin, Oral Glucose Tolerance Test, HOMA index
- Glucose metabolism parameters [ Time Frame: Week 10 (end of treatment) ]Fasting serum glucose, Fasting serum insulin, Oral Glucose Tolerance Test, HOMA index
- Lipid metabolism biomarkers [ Time Frame: Week 0 (baseline) ]Serum total-cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerols, free fatty acids, ketone bodies.
- Lipid metabolism biomarkers [ Time Frame: Week 10 (end of treatment) ]Serum total-cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerols, free fatty acids, ketone bodies.
- Blood Pressure and Cardiovascular Risk biomarkers [ Time Frame: Baseline ]Blood pressure, PAI-1 and VEGF will be measured.
- Blood Pressure and Cardiovascular Risk biomarkers [ Time Frame: Week 10 (end of treatment) ]Blood pressure, PAI-1 and VEGF will be measured.
- Energy expenditure [ Time Frame: Baseline ]Energy expenditure will be estimated by indirect calorimetry, and T3, T4 and TSH levels will be analysed by ELISA kits
- Energy expenditure [ Time Frame: Week 10 (end of treatment) ]Energy expenditure will be estimated by indirect calorimetry, and T3, T4 and TSH levels will be analysed by ELISA kits
- Satiety [ Time Frame: Baseline ]Satiety will be estimated by using a VAS questionnaire
- Satiety [ Time Frame: Week 10 (end of treatment) ]Satiety will be estimated by using a VAS questionnaire
- Serum inflammation biomarkers [ Time Frame: Baseline ]TNF-alpha, IL-6, C-reactive protein, serum A-amiloid, Leptin, Adiponectin, Visfatin
- Serum inflammation biomarkers [ Time Frame: Week 10 (end of treatment) ]TNF-alpha, IL-6, C-reactive protein, serum A-amiloid, Leptin, Adiponectin, Visfatin
- Serum oxidative stress biomarkers [ Time Frame: Baseline ]Total and Reduced Glutathione, Glutathione Peroxidase, MDA, Superoxide Dismutase-2 (Mn-SOD).
- Serum oxidative stress biomarkers [ Time Frame: Week 10 (end of treatment) ]Total and Reduced Glutathione, Glutathione Peroxidase, MDA, Superoxide Dismutase-2 (Mn-SOD).
- Adipose tissue gene profile and function analysis [ Time Frame: Week 10 (end of treatment) ]A biopsy (2 g) of subcutaneous abdominal periumbilical area adipose tissue will be obtained. In order to identify clusters/pathways of genes regulated by the supplementation of EPA and LA, microarray gene profiling will be performed in adipose tissue from the 4 groups after the nutritional intervention. If possible primary explant culture of adipose tissue biopsies will be also carried out.
- Metabolomic and lipidomic profile [ Time Frame: Baseline ]Samples of plasma and 24-h urine will be analysed by Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS), and Nuclear Magnetic Resonance (NMR), and Bidimensional Gas Chromatography-Mass Spectrometry (BC-MS).
- Metabolomic and lipidomic profile [ Time Frame: Week 10 (end of treatment) ]Samples of plasma and 24-h urine will be analysed by Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS), and Nuclear Magnetic Resonance (NMR), and Bidimensional Gas Chromatography-Mass Spectrometry (BC-MS).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Women
- Ages between 20 and 45 years, and with regular menstrual cycles
- Body Mass Index (BMI) between 27.5 and 39.9 kg/m2
- Weight unchanged (± 3 kg) for the last 3 months
- All subjects should have an overall physical and psychological condition that the investigator believes is in accordance with the overall aim of the study.
Exclusion Criteria:
- Use of prescription medication
- To suffer from any chronic metabolic or obesity related disease, hepatic or renal systemic disease: Hypertension, dislipidemia, type 1 or 2 diabetes, thyroid function disorders, cirrhosis, fatty liver, etc.
- Food allergies or food intolerance expected to come up during the study
- Special diets (Atkins, vegetarian, etc.) prior three months the start of the study.
- Eating disorders
- Surgically treated obesity
- Pregnant or lactating women or planning to be pregnant in the next two months
- Alcohol or drug abuse (based on clinical parameters)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138774
Spain | |
Department of Nutrition, Food Science, Physiology and Toxicology. University of Navarra | |
Pamplona, Navarra, Spain, 31008 |
Principal Investigator: | Maria J Moreno-Aliaga, PhD | University of Navarra | |
Study Director: | Alfredo Martínez, PhD | University of Navarra | |
Study Chair: | Santiago Navas-Carretero, PhD | University of Navarra |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Clinica Universidad de Navarra, Universidad de Navarra |
ClinicalTrials.gov Identifier: | NCT01138774 |
Other Study ID Numbers: |
OBEPALIP |
First Posted: | June 7, 2010 Key Record Dates |
Last Update Posted: | May 28, 2015 |
Last Verified: | February 2012 |
Obesity Calorie restriction Eicosapentaenoic acid (EPA) Lipoic acid Weight loss Insulin sensitivity |
Lipid metabolism Adipokines Inflammation Oxidative stress Adipose tissue gene profile Metabolomic profile |
Obesity Insulin Resistance Overnutrition Nutrition Disorders Overweight Body Weight Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
Thioctic Acid Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vitamin B Complex Vitamins Micronutrients |